- Home
- / Achillion Pharmaceuticals
- / Financials
Header placeholder lorem ipsum dolor sit amet, consectetur adipiscing elit.
Achillion Pharmaceuticals financials data including stock price, CreditSafe score, income statement, balance sheet, and cash flow.
Stock Price
$1.1
2023-11-27
Market Capitalization
$23.7 M
2023-11-27
Revenue
$15 M
FY, 2016
CreditSafe Score
?
Score changed on Jul 21, 2026
Premium Content only available in Craft’s Intelligence Portal
View 30+ financial ratio metrics including price-to-earnings ratio, debt-to-assets ratio, gross profit margin, and more.
Financial ratio metrics help evaluate the financial strength of a company, and help raise red flags that can indicate potential risk, fulfillment challenges, or even possible bankruptcy.
Learn moreFinancial Statements
| USD | FY, 2011 | FY, 2012 | FY, 2013 | FY, 2014 | FY, 2015 | FY, 2016 | FY, 2017 | FY, 2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 247.0K | 2.6M | 66.1M | 15.0M | ||||
| Revenue growth, % | -77.3% | |||||||
| General and administrative expense | 9.2M | 10.9M | 12.7M | 15.9M | 24.7M | 20.7M | 24.5M | 23.9M |
| Operating expense total | 44.6M | 49.9M | 59.5M | 69.4M | 81.2M | 79.9M | 89.6M | 75.9M |
| EBIT | (44.3M) | (47.3M) | (59.5M) | (69.4M) | (15.1M) | (64.9M) | (89.6M) | (75.9M) |
| EBIT margin, % | -17954.3% | -1814.1% | -22.8% | -432.4% | ||||
| Investment income | 186.0K | 1.2M | 3.2M | 4.4M | 5.7M | |||
| Interest income | 234.0K | 582.0K | 455.0K | |||||
| Interest expense | 45.0K | 68.0K | 52.0K | 37.0K | ||||
| Income tax expense | 3.3M | 699.0K | (23.2M) | |||||
| Net Income | (44.2M) | (47.1M) | (58.9M) | (69.0M) | (5.0M) | (61.7M) | (85.2M) | (70.3M) |